swerte casino login

Glufosfamide is under clinical development by Eleison Pharmaceuticals and currently in Phase III for Metastatic Adenocarcinoma of The Pancreas. According to GlobalData, Phase III drugs for Metastatic Adenocarcinoma of The Pancreas have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Glufosfamide overview Glufosfamide is under development for the treatment of metastatic pancreatic adenocarcinoma. The drug candidate is administered intravenously. Glufosfamide is beta-D-glucosyl-isophosphoramide mustard and a glucose-conjugated prodrug. It is an analogue of ifosfamide. It acts as an alkylating agent and stops tumor growth by cross-linking bases in DNA double-helix strands, directly attacking DNA. The drug candidate was also under development for the treatment of recurrent sensitive small-cell lung cancer, soft tissue sarcoma, epithelial ovarian cancer, peritoneal serous cancer, or carcinoma of the fallopian tube.It was under development for the treatment of metastatic pancreatic adenocarcinoma. Eleison Pharmaceuticals overview Eleison Pharmaceuticals is a drug development company that acquires, develops, and commercializes clinical stage drug candidates for orphan cancers. The company’s pipeline products include glufosfamide and inhaled lipid-complexed cisplatin. Its glufosfamide is an analog of chemotherapeutic agent for treatment of metabolically active tumors and hypoxic tumor regions. Eleison Pharmaceuticals’ inhaled lipid-complexed cisplatin is a sustained release formulation of cisplatin in a nanoscale lipid based complex used for pediatric osteosarcoma – bone cancer. The company provides clinical trials for pancreatic cancer and osteosarcoma. Eleison Pharmaceuticals is headquartered in Princeton, New Jersey, the US. For a complete picture of Glufosfamide’s drug-specific PTSR and LoA scores, This content was updated on 12 April 2024 From Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors. , the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s .The Los Angeles Chargers activated running back J.K. Dobbins from injured reserve on Friday. Dobbins is formally listed as questionable but figures to be the team's top running threat for Saturday's road game against the New England Patriots. Teammate Gus Edwards (ankle) was ruled out Thursday. Dobbins has missed the past four games since sustaining a knee injury against the Baltimore Ravens on Nov. 25. He was a full practice participant Thursday before receiving the questionable label. The injury-prone Dobbins was enjoying a solid season prior to the knee ailment, with 766 yards and eight touchdowns on the ground and 28 receptions for 134 yards in 11 games. His career high for rushing yardage is 805 for the Ravens in 2020. Dobbins' return comes with the Chargers (9-6) just one win from clinching an AFC wild-card playoff spot. Los Angeles also elevated safeties Eddie Jackson and Kendall Williamson from the practice squad. --Field Level Mediaswerte casino login 。

None

The midseason four-game winning streak that lifted the Arizona Cardinals into the playoff picture seemed as though it happened fast. Their subsequent free fall has been even more jarring. The Cardinals could have moved into a tie for first place in the NFC West with a home win over the Seattle Seahawks on Sunday. Instead, they were thoroughly and are now tied for last in the tightly packed division. Arizona has lost three straight and will face an uphill battle to return to the playoffs for the first time since 2021. The Seahawks (8-5) are in first place, followed by the Rams (7-6), Cardinals (6-7) and 49ers (6-7). Even more daunting for their playoff hopes, the Cardinals lost both of their games against the Seahawks this season, meaning a tiebreaker would go to Seattle. Four games remain. “I just told them we put ourselves in a little bit of a hole now, but all you can do is attack tomorrow, learn tomorrow and have a good week of practice,” second-year coach Jonathan Gannon said. There are plenty of reasons the Cardinals lost to the Seahawks, including Kyler Murray's two interceptions, a handful of holding penalties, a porous run defense and a brutal missed field goal. It all adds up to the fact Arizona is playing its worst football of the season at a time when it needed its best. “I’m sure we’ll stick to our process, but we have to tweak some things,” Gannon said. "I have to tweak some things.” It's probably faint praise, but the Cardinals did make the game interesting in the second half while trying to fight back from a 27-10 deficit. Murray's shovel pass to James Conner for a 2-yard touchdown and subsequent 2-point conversion cut the margin to 27-18. The Cardinals had a chance to make it a one-score contest early in the fourth quarter, but Chad Ryland's 40-yard field goal attempt bounced off the left upright. “I thought we spotted them a lot of points there, but then we battled back,” Gannon said. “I appreciate their effort. That was good. We battled back there, had a couple chances to even cut the lead a little more, but ultimately didn’t get it done." Murray's in a bit of a mini-slump after throwing two interceptions in back-to-back games for the first time in his career. He also didn't do much in the run game against the Seahawks, with 16 yards on three carries. The quarterback's decision-making was nearly flawless for much of the season and the Cardinals need that good judgment to return. “I’m not looking at it like I have to try to be Superman,” Murray said. “I don’t think that’s the answer. I just need to play within the offense like we’ve done for the majority of the season. Today, I didn’t. Like I said, throwing two picks puts yourself behind the eight ball.” Said Gannon: “I thought he stuck in there and made some big time throws, though, but he has to protect the ball a little bit better. That’s not just him, that’s all 11. So there’ll be a lot of corrections off those plays." The defense didn't have its best day, but it's not Budda Baker's fault. The two-time All-Pro safety is having another phenomenal season and was all over the field against the Seahawks, finishing with 18 tackles. Baker's energy is relentless and he's the unquestioned leader of a group that has been better than expected this season, even with Sunday's mediocre performance. Left tackle Paris Johnson Jr. had a tough day, getting flagged for holding three times, though one of those penalties was declined by the Seahawks. The second-year player moved from right tackle to the left side during the offseason and the transition has gone well, but Sunday was a step backward. The Cardinals remain fairly healthy. DL Roy Lopez (ankle) and P Blake Gillikin (ankle) left Sunday's game, but neither injury is expected to be long term. 9 — It looks as if the Cardinals will go a ninth straight season without winning the NFC West. The last time they won the division was 2015 with coach Bruce Arians and a core offense of quarterback Carson Palmer, running back David Johnson and receiver Larry Fitzgerald. The Cardinals are in must-win territory now for any chance at the playoffs. They'll host the New England Patriots on Sunday. AP NFL:

CHICAGO (AP) — CHICAGO (AP) — Oil-Dri Corp. of America (ODC) on Monday reported earnings of $16.4 million in its fiscal first quarter. On a per-share basis, the Chicago-based company said it had profit of $2.25. The maker of products for soil in the agriculture, horticulture and sports sectors posted revenue of $127.9 million in the period. This story was generated by Automated Insights ( http://automatedinsights.com/ap ) using data from Zacks Investment Research. Access a Zacks stock report on ODC at https://www.zacks.com/ap/ODCLions head into NFC title game rematch vs. 49ers seeking top seed more than revenge

Ball security, rebounding key for CU Buffs in rematch against No. 3 Iowa State

Cardinals' sudden 3-game tailspin has turned their once solid playoff hopes into a long shotShort-handed Eagles add QB Ian Book to practice squad